Born 1965. CEO since 2025, Chairman since 2019 and board member since 2016.
Education: Viktor has an M.D, a Ph.D. and an Associate Professor degree from Karolinska Institutet.
Experience: Viktor has over 19 years of venture capital experience focused on life science with several investments, significant fundraisings, exits and IPOs. He was responsible for Life science at SEB Venture Capital during the years 2002-2016. During his appointment at SEB Venture Capital he also served as a board member in several biotech and medtech companies. Prior to this, Viktor worked as Associate Professor and senior consultant at Karolinska Institution/hospital in Huddinge. He also has significant experience from pre-clinical and clinical research within different biotech and medtech companies.
Other current assignments: CEO and board member of KCIF Fund Management AB. Chairman of the board of Modus Therapeutics AB and Modus Therapeutics Holding AB. CEO of Karolinska Development AB. Board member of Foendo Oy, Dilafor AB, Dilafor Incentive AB, OssDsign AB and KDev Investments AB. Deputy board member of Promimic AB and Svenska Vaccinfabriken Produktionen AB.
Holdings in the Company: –
Independent in relation to the Company and its management but not independent in relation to major shareholders.
Born 1967. CSO since 2022.
Education: Magnus has a master’s degree in organic chemistry and a Ph.D. in biotechnology from the Royal Institute of Technology in Stockholm and an Executive MBA from Stockholm Business School, Stockholm University.
Experience: Magnus Doverskog has more than 20 years industry experience from discovery and development projects of both small molecules and biologics. Senior positions at Astra Pain Control, Biovitrum AB, and as CEO of IMED AB. Post doctorial research at the European Molecular Biology Laboratory (EMBL) in Heidelberg where he obtained a Marie Curie individual Fellowship. Magnus also held the role as CEO of Umecrine Cognition between 2012-2022.
Other current assignments: –
Holdings in the Company: 10,369 shares.
Born 1963. Medical Director since March 2024.
Education: Roberto has a Master’s degree in Medicine and Surgery and a postgraduation degree in Liver and Metabolic diseases from University of Rome “La Sapienza”
Experience: Roberto Camerini has 35 years industry experience and over the years has held executive roles in Clinical Research and Development in international biopharmaceutical companies: Abbott, Serono, Sigma-tau, Alfasigma, Cosmo, Reithera and Epigen Therapeutics. He is the founder and member of the board of the NIBIT Foundation (Italian Network for Tumor Biotherapy). He is co-author of several publications in international journals.
Other current assignments: Professor of Experimental Clinical Methodology at the School of Oncology of the University of Siena.
Holdings in the Company: –
Born 1968. CFO since 2021.
Education: Hans Christopher has an M.Sc. in Economics from the Stockholm School of Economics.
Experience: Hans Christopher “HC” Toll has previous experience as CFO for companies within several industries since 2004, such as Portescap SA and KIN Group, and currently has consulting assignments for companies such as Cedergrenska AB, EcoBloom Sweden AB, Yabie AB and WeHype Global AB. Furthermore, he has experience from previous listings, and was during 2016 CFO for AIK Fotboll AB when it was listed on NGM, and assisted in the listings of FundedByMe and Cedergrenska AB on Nasdaq First North Growth Market.
Other current assignments: Board member of Livgrenadjärmässen Hotell- Fest- Konferens in Linköping AB, Hydra Consulting AB and HC Toll Control AB
Holdings in the company: –
